This study investigates the safety and tolerability of an investigational cell therapy in patients with relapsed/refractory pancreatic cancer. The purpose of this study is to understand how the therapy works for people who have not responded to previous treatments.
The study evaluates the effects of the investigational cell therapy, focusing on its safety and how well it is tolerated by patients. Researchers are looking to see if the therapy can be given safely at different dose levels.
- Who can participate: Adults aged 18 to 75 years with advanced pancreatic cancer that has worsened after standard treatments may participate. Participants must have adequate organ function, an expected survival of at least 3 months, and must sign an informed consent.
- Study details: Participants will receive the investigational cell therapy and be monitored for safety and tolerability.
How understandable was the trial content above?
Hard to understand
Easy to understand